Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Johnson & Johnson offers robust near-term return potential backed by strong Q4 2025 results, significant FDA approvals and pipeline catalysts, plus positive short-term technical momentum supporting a bullish outlook into early 2026.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High Profitability ⢠Robust Cash Flow ⢠Balance Sheet Risk JNJ delivers strong profitability and cash flow, but its premium valuation, elevated debt, and large intangible-asset exposure warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Persistent uptrend ⢠Resistance rejection ⢠Support watch Support Level: $271â$272 (stronger: $265â$266) Resistance Level: $278â$279 JNJ remains bullish over the last month, but with resistance at $278â$279 and support at $271â$272, consider holding while monitoring for consolidation or a support break.
Sentiment & News
Key News Insights: ⢠Pipeline Momentum ⢠Patent Headwinds ⢠Litigation Exposure J&J's strong pharma pipeline and raised guidance support growth, but MedTech softness, talc litigation, patent expirations, and premium valuation warrant caution.
AI Summary
JNJ is now a premium-priced growth story, so investors should hold or add only if Innovative Medicine can convert launches into margin-accretive earnings fast enough to offset Stelara erosion and MedTech weakness; otherwise, talc uncertainty and a ~30x P/E leave meaningful downside risk.
Description
Johnson & Johnson develops, manufactures and sells healthcare products worldwide through three principal businesses: Consumer Health, Pharmaceuticals and MedTech. Its Consumer Health unit offers household personal-care and over-the-counter medicines, the Pharmaceuticals division markets prescription therapies across immunology, infectious disease, CNS, oncology, cardiovascular and metabolic indications, and the MedTech business supplies devices for cardiovascular, neurovascular, orthopaedic, surgical and vision care. The company distributes to retailers, wholesalers, hospitals and healthcare professionals and is headquartered in New Brunswick, New Jersey; it was founded in 1886.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jan 23 | Jan 30 | JNJ | Johnson & Johnson | Johnson & Johnson offers robust near-term return potential backed by strong Q4 2025 results, significant FDA approvals and pipeline catalysts, plus positive short-term technical momentum supporting a bullish outlook into early 2026. | Closed | +3.2% |
| Nov 17 | Nov 24 | JNJ | Johnson & Johnson | Strong Q3 2025 beat with raised guidance, multiple near-term FDA approvals boosting revenue prospects, strategic M&A enhancing growth, robust free cash flow, and positive technical momentum just below the upper Bollinger band support a favorable near-term price appreciation setup. | Closed | +3.2% |